Cyprotex PLC Publication of Annual Report & Notice of AGM (9859N)
May 22 2015 - 2:00AM
UK Regulatory
TIDMCRX
RNS Number : 9859N
Cyprotex PLC
22 May 2015
Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")
Publication of Annual Report & Accounts 2014
& Notice of AGM - Update
Cyprotex PLC announces that its 2014 Annual Report and Accounts
for the year ending 31 December 2014, together with the Notice of
the Annual General Meeting and associated proxy form will today be
posted to shareholders
The Annual Report and Accounts 2014 are available from the
Company's website, www.cyprotex.com
Further to the Final Results announcement of 15 April 2015,
Cyprotex PLC's Annual General Meeting will now be held on Wednesday
17 June 2015 (and not on 25 June 2015) at 10.00 a.m. at the offices
of N+1 Singer Advisory LLP, One Bartholomew Lane, London EC2N 2AX
.
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20
Cyprotex) 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors:
Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites in Macclesfield, near Manchester in
the UK, Watertown, MA and Kalamazoo MI in the US. The Company was
established in 1999 and works with more than 1,000 partners within
the pharmaceutical and biotech industry, cosmetics and personal
care industry and the chemical industry. Cyprotex acquired Apredica
and the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services, extending from early drug
discovery through to IND submission. The acquisition of the assets
and business of CeeTox in January 2014 has enabled Cyprotex to
expand its range of services to target the personal care, cosmetics
and chemical industries. The Company's core capabilities include
high quality in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services,
including our proprietary CellCiphr(R) toxicity prediction
technology, predictive modelling using PBPK and QSAR techniques,
including Cloe(R) PK for in vivo PK prediction, and a range of
skin, ocular and endocrine disruption services. For more
information, see www.cyprotex.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDURSDBGUB
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
